Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
225 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2016', provides an overview of the Metastatic Adenocarcinoma of The Pancreas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Metastatic Adenocarcinoma of The Pancreas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Adenocarcinoma of The Pancreas and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas - The report reviews pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Metastatic Adenocarcinoma of The Pancreas therapeutics and enlists all their major and minor projects - The report assesses Metastatic Adenocarcinoma of The Pancreas therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Metastatic Adenocarcinoma of The Pancreas Overview 10 Therapeutics Development 11 Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview 11 Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis 12 Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies 13 Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes 15 Metastatic Adenocarcinoma of The Pancreas - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies 19 Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes 21 Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development 22 AbbVie Inc. 22 Aduro BioTech, Inc. 23 Array BioPharma Inc. 24 Axcentua Pharmaceuticals AB 25 Berg LLC 26 Boehringer Ingelheim GmbH 27 Boston Biomedical, Inc. 28 CTI BioPharma Corp. 29 CytRx Corporation 30 Eleison Pharmaceuticals LLC 31 Gilead Sciences, Inc. 32 GlaxoSmithKline Plc 33 Incyte Corporation 34 Merrimack Pharmaceuticals, Inc. 35 NewLink Genetics Corporation 36 Novartis AG 37 Oncolytics Biotech Inc. 38 Pfizer Inc. 39 Phoenix Biotechnology, Inc. 40 Plexxikon Inc. 41 Sanofi 42 Targovax AS 43 Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment 44 Assessment by Monotherapy Products 44 Assessment by Target 45 Assessment by Mechanism of Action 48 Assessment by Route of Administration 51 Assessment by Molecule Type 53 Drug Profiles 55 aldoxorubicin hydrochloride - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 AXP-10711 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 BI-853520 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 binimetinib - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Cellular Immunotherapy for Cancer - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 ceritinib - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 CRS-207 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 glufosfamide - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 GS-5745 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 GSK-2256098 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 ibrutinib - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 INCB-52793 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 indoximod - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 irinotecan hydrochloride - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 LGK-974 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 MesoCART - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 napabucasin - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 paclitaxel - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 palbociclib - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 PBI-05204 - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 pelareorep - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 plerixafor - Drug Profile 117 Product Description 117 Mechanism of Action 117 R&D Progress 117 PLX-7486 - Drug Profile 120 Product Description 120 Mechanism of Action 120 R&D Progress 120 PRI-724 - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 ribociclib - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 SGT-53 - Drug Profile 126 Product Description 126 Mechanism of Action 126 R&D Progress 126 sonidegib phosphate - Drug Profile 128 Product Description 128 Mechanism of Action 128 R&D Progress 128 TG-01 - Drug Profile 132 Product Description 132 Mechanism of Action 132 R&D Progress 132 tosedostat - Drug Profile 134 Product Description 134 Mechanism of Action 134 R&D Progress 134 ubidecarenone - Drug Profile 137 Product Description 137 Mechanism of Action 137 R&D Progress 137 ulixertinib - Drug Profile 139 Product Description 139 Mechanism of Action 139 R&D Progress 139 Vaccine for Oncology - Drug Profile 140 Product Description 140 Mechanism of Action 140 R&D Progress 140 Metastatic Adenocarcinoma of The Pancreas - Recent Pipeline Updates 141 Metastatic Adenocarcinoma of The Pancreas - Dormant Projects 219 Metastatic Adenocarcinoma of The Pancreas - Discontinued Products 220 Metastatic Adenocarcinoma of The Pancreas - Product Development Milestones 221 Featured News & Press Releases 221 Jan 25, 2016: Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium 221 Jan 07, 2016: Baxalta Announces Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug Submission 222 Jun 25, 2015: MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer 223 Appendix 224 Methodology 224 Coverage 224 Secondary Research 224 Primary Research 224 Expert Panel Validation 224 Contact Us 224 Disclaimer 225
List of Tables
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H1 2016 11 Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 Metastatic Adenocarcinoma of The Pancreas - Pipeline by AbbVie Inc., H1 2016 22 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Aduro BioTech, Inc., H1 2016 23 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Array BioPharma Inc., H1 2016 24 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Axcentua Pharmaceuticals AB, H1 2016 25 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Berg LLC, H1 2016 26 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boehringer Ingelheim GmbH, H1 2016 27 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boston Biomedical, Inc., H1 2016 28 Metastatic Adenocarcinoma of The Pancreas - Pipeline by CTI BioPharma Corp., H1 2016 29 Metastatic Adenocarcinoma of The Pancreas - Pipeline by CytRx Corporation, H1 2016 30 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Eleison Pharmaceuticals LLC, H1 2016 31 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Gilead Sciences, Inc., H1 2016 32 Metastatic Adenocarcinoma of The Pancreas - Pipeline by GlaxoSmithKline Plc, H1 2016 33 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Incyte Corporation, H1 2016 34 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 35 Metastatic Adenocarcinoma of The Pancreas - Pipeline by NewLink Genetics Corporation, H1 2016 36 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Novartis AG, H1 2016 37 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Oncolytics Biotech Inc., H1 2016 38 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Pfizer Inc., H1 2016 39 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Phoenix Biotechnology, Inc., H1 2016 40 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Plexxikon Inc., H1 2016 41 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Sanofi, H1 2016 42 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Targovax AS, H1 2016 43 Assessment by Monotherapy Products, H1 2016 44 Number of Products by Stage and Target, H1 2016 46 Number of Products by Stage and Mechanism of Action, H1 2016 49 Number of Products by Stage and Route of Administration, H1 2016 52 Number of Products by Stage and Molecule Type, H1 2016 54 Metastatic Adenocarcinoma of The Pancreas Therapeutics - Recent Pipeline Updates, H1 2016 141 Metastatic Adenocarcinoma of The Pancreas - Dormant Projects, H1 2016 219 Metastatic Adenocarcinoma of The Pancreas - Discontinued Products, H1 2016 220
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
